Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
about
Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating OverviewTreatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations.Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.Metabolic monitoring and management among clozapine users.The impact of clozapine on hospital use: a systematic review and meta-analysis.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Clozapine as a Model for Antipsychotic Development.Clozapine and concomitant medications: Assessing the completeness and accuracy of medication records for people prescribed clozapine under shared care arrangements.Low dose clozapine controls adult-onset psychosis associated with the neurogenic ataxia-retinitis pigmentosa (NARP) mutation.Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience.Clozapine in primary care.Clozapine and Gastrointestinal Hypomotility.Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study.Learned lessons from patients who take clozapine: A case study.Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis.Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.The significance of sampling time in therapeutic drug monitoring of clozapine.CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard?Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial.Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and AgranulocytosisThe acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analysesClozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysisAntipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
P2860
Q28077687-7D1D9ADC-D22D-4AE0-97D1-F9A48F168FB2Q38647035-E5DF6DE4-DD3B-4C1D-91EA-5B171E2353FCQ38659786-BBBD3E0A-7F18-4F8A-999C-1D06042C7EBAQ38706468-0519F058-97CC-4B5B-BA84-CFC0BDD34D00Q38945107-51A9A875-96AE-465B-8E00-FB61BEE32E2AQ39117168-45BD9292-4B85-40F9-8A3D-990914232074Q39233330-61D37DFD-4B6F-42CC-9254-B810349332A9Q39400094-2721BCD3-DE07-4B64-8DD3-69501E1337CFQ40466435-FF7EEF2D-D245-4B00-87A4-BF4299D3CD80Q42012524-E1700293-7E8A-424E-B18C-4ABEAA3AEFE0Q47550545-31825F43-01F3-4034-ABDD-A4725F5E5F69Q47551390-A761CA8B-070C-432A-AB4D-4E45F9632107Q47565362-855D9504-80C5-4092-90DD-6FBC6C781812Q47568761-75EB2274-8F49-41A3-9654-2D70EB4AB550Q47590406-6A4B73C6-738B-48D5-8BDC-E707EA7B8A60Q47618856-9BBEE78C-B488-44D2-82D8-46F9973E927EQ47628101-9A826A6C-41D0-4DB6-8103-920A432D530FQ48314103-08438CAB-A821-4985-9BCA-E68BF7CD31E7Q51026132-02E3A99D-FBAC-48F5-8661-C7BB76456F0EQ53071728-FAFA56B4-5C89-481E-91D9-9AB76B9B7C80Q53748909-E3610870-4F10-4D73-B3D6-87A8BF4BCDE8Q55232340-C21CF7C1-ABF3-4A1B-A2ED-F28F24A98E71Q55423236-AD4F39BE-7749-4000-811B-3CFA5A0A58B9Q57491589-032CEAA2-0AED-437F-BEA8-81E8E613E002Q57817726-156127E0-F807-4152-8E93-252B8C178F89Q58738328-6610200B-6FDE-4BB4-ADA9-CAAE4D993D19Q58791341-72681EDF-0673-48BF-9656-FE55109BEBB2
P2860
Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Clozapine v. first- and second ...... atic review and meta-analysis.
@ast
Clozapine v. first- and second ...... atic review and meta-analysis.
@en
Clozapine v. first- and second ...... atic review and meta-analysis.
@nl
type
label
Clozapine v. first- and second ...... atic review and meta-analysis.
@ast
Clozapine v. first- and second ...... atic review and meta-analysis.
@en
Clozapine v. first- and second ...... atic review and meta-analysis.
@nl
prefLabel
Clozapine v. first- and second ...... atic review and meta-analysis.
@ast
Clozapine v. first- and second ...... atic review and meta-analysis.
@en
Clozapine v. first- and second ...... atic review and meta-analysis.
@nl
P2093
P1476
Clozapine v. first- and second ...... matic review and meta-analysis
@en
P2093
Lara McCartney
Romi Goldschlager
Steve Kisely
P304
P356
10.1192/BJP.BP.115.177261
P407
P50
P577
2016-07-07T00:00:00Z